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Introduction. In a degenerative disorder such as Parkinson’s disease (PD), it is important to establish clinical stages that allow to
know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr’s motor stage (H&Y) and the
nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the
disability and the patient’s quality of life (QoL) with regard to a defined clinical stage. Materials and Methods. Cross-sectional
study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4,
stage IV/V) and NMSB (A: NMSS� 0–20; B: NMSS� 21–40; C: NMSS� 41–70; D: NMSS≥ 71) in 16 stages (HY.NMSB, from 1A
to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL
(Activities of Daily Living) scale. Results. A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB
(p< 0.0001). Combining both (HY.NMSB), patients in stages 1C and 1D and 2C and 2D had significantly worse QoL and/or less
autonomy for ADL than those in stages 2A and 2B and 3A and 3B, respectively (p< 0.005; e.g., PDQ-39SI in 1D [n� 15] vs 2A
[n� 101]: 28.6± 17.1 vs 7.9± 5.8; p< 0.0001). Conclusion. +e HY.NMSB scale is simple and reflects the degree of patient in-
volvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater
NMS burden.
1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenera-
tive disorder causing motor and nonmotor symptoms
(NMS) that result in disability, loss of patient autonomy,
and caregiver burden [1]. In a degenerative disease, it is
important to establish clinical stages that allow the de-
termination of disease progression for a patient based on
different specific symptoms. Ideally, this clinical gradua-
tion should be simple to carry out so that it can be used
universally in clinical practice. In the case of PD, and based
on the classic motor symptoms of the disease, the Hoehn
and Yahr (H&Y) scale is used to describe the progression of
PD [2]. +e scale was originally described in 1967 and
included stages 1 through 5. It has since been modified with
the addition of stages 1.5 and 2.5 to help describe the
intermediate course of the disease [3]. +is rating system
has been largely supplemented by, firstly, the Unified
Parkinson’s Disease Rating Scale (UPDRS) [4], and more
recently, the MDS-Unified Parkinson’s Disease Rating
Scale (MDS-UPDRS) [5], which assess limitation of Ac-
tivities of Daily Living (ADL) and NMS. However, eval-
uating the patient using the UPDRS and/or MDS-UPDRS
takes time; specialization is required and, importantly, do
not allow the patient to be classified into a clearly differ-
entiated stage, and several NMS are not included. Validated
tools for assessing NMS such as the NMSQuest [6] and the
nonmotor symptoms scale (NMSS) [7] are used both in
trials and in clinical practice. Furthermore, it has been
demonstrated that NMS are an important determinant and
deteriorating factor of the quality of life (QoL) of PD
patients [8, 9]. Not only motor symptoms but also NMS
increase in their severity and burden over time, increasing
patients’ disability, with additional worsening of their QoL,
as well as caregivers’ burden and consequential con-
sumption of social resources by increasing societal costs.
+at is why for staging PD it would be necessary to combine
a motor with a nonmotor scale, which would allow the
patient to be classified into stages considering both the
degree of motor and nonmotor involvement.
Recently, it has been suggested that gradation of PD
according to the motor impairment and burden of NMS is
an unmet need for an appropriate management of patients
[10]. Ray Chaudhuri et al. proposed a PD classification by
H&Y staging and NMS burden level and demonstrated a
correlation of both H&Y staging and NMS burden to dis-
ability and QoL [11]. However, QoL and autonomy for ADL
regarding the stage considering both together, motor and
nonmotor stages, were not analyzed. +e H&Y scale pro-
vides quick information about the patient’s condition, but
since it does not include NMS, it is not very sensitive to
reflect the real impact of that condition. Our hypothesis is
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that a patient with a lower H&Y stage but a greater NMS
burden may present a worse QoL and greater disability than
another patient with amore advancedH&Y stage but a lower
NMS burden, so it would be beneficial to combine both
aspects on a scale. +e aim of this study was to classify PD
patients from the COPPADIS cohort [12, 13], regarding
H&Y and NMS burden combined in a specific scale
(HY.NMSB), and to compare QoL and autonomy for ADL
between patients in a different HY.NMSB stages.
2. Materials and Methods
PD patients recruited from 35 centers of Spain from the
COPPADIS cohort [13] from January 2016 to November 2017
were included in the study. Methodology about COPPADIS-
2015 study can be consulted in https://bmcneurol.
biomedcentral.com/articles/10.1186/s12883-016-0548-9.
+is is a multicenter, observational, longitudinal-pro-
spective, 5-year follow-up study designed to analyze disease
progression in a Spanish population of PD patients.+e data
for the present study (cross-sectional study) were obtained
from the baseline evaluation. All patients included were
diagnosed according to UK PD Brain Bank criteria. Ex-
clusion criteria were as follows: non-PD parkinsonism,
dementia (Mini Mental State Examination (MMSE)< 26),
age <18 or >75 years, inability to read or understand the
questionnaires, to be receiving any advanced therapy
(continuous infusion of levodopa or apomorphine and/or
with deep brain stimulation), and the presence of comor-
bidity, sequelae, or any disorder that could interfere with the
assessment.
Information on sociodemographic aspects, factors re-
lated to PD, comorbidity, and treatment was collected.
Motor and NMS were evaluated using different validated
scales [12]. In patients with motor fluctuations, the motor
assessment (H&Y and UPDRS) was conducted during the
OFF state (without medication in the last 12 hours; H&Y-
OFF and UPDRS-III-OFF) and during the ON state (H&Y-
ON and UPDRS-III-ON). However, in patients without
motor fluctuations, it was only performed without medi-
cation (first thing in the morning without taking medication
in the previous 12 hours). Moreover, in PD patients with
motor fluctuations, the nonmotor assessment was con-
ducted during the ON state [12]. +e NMSS [7] was used for
assessing NMS. +is includes 30 items, each with a different
nonmotor symptom. +e symptoms refer to the 4 weeks
prior to assessment.+e total score for each item is the result
of multiplying the frequency (0, never; 1, rarely; 2, often; 3,
frequent; 4, very often) x severity (1, mild; 2, moderate; 3,
severe) and will vary from 0 to 12 points. +e scale score
ranges from 0 to 360 points. +e items are grouped into 9
different domains: (1) cardiovascular (items 1 and 2; score, 0
to 24); (2) sleep/fatigue (items 3, 4, 5, and 6; score, 0 to 48);
(3) depression/apathy (items 7, 8, 9, 10, 11, and 12; score, 0 to
72); (4) perceptual problems/hallucinations (items 13, 14,
and 15; score, 0 to 36); (5) attention/memory (items 16, 17,
and 18; score, 0 to 36); (6) gastrointestinal tract (items 19, 20,
and 21; score, 0 to 36); (7) urinary symptoms (items 22, 23,
and 24; score, 0 to 36); (8) sexual dysfunction (items 25 and
26; score, 0 to 24); (9) miscellaneous (items 27, 28, 29, and
30; score, 0 to 48).
+ree different instruments were used to assess QoL: (1)
the PDQ-39 [14]; (2) a rating of global perceived QoL (PQ-
10) on a scale from 0 (worst) to 10 (best) [8, 15]; and (3) the
EUROHIS-QOL8 [16]. +e PDQ-39 is a PD-specific ques-
tionnaire that assesses the patients’ health-related QoL.
+ere are 39 items grouped into 8 domains: (1) mobility
(items 1 to 10); (2) Activities of Daily Living (items 11 to 16);
(3) emotional well-being (items 17 to 22); (4) stigma (items
23 to 26); (5) social support (items 27 to 29); (6) cognition
(items 30 to 33); (7) communication (items 34 to 36); and (8)
pain and discomfort (items 37 to 39). For each item, the
score may range from 0 (never) to 4 (always). +e symptoms
refer to the 4 weeks prior to assessment. Domain total scores
are expressed as a percentage of the corresponding maxi-
mum possible score, and a Summary Index is obtained as
average of the domain scores. +e EUROHIS-QOL8 is an 8-
item global QoL questionnaire (quality of life, health status,
energy, autonomy for Activities of Daily Living, self-esteem,
social relationships, economic capacity, and habitat) derived
from the WHOQOL-BREF. For each item, the score ranges
from 0 (not at all) to 5 (completely). +e total score is
expressed as the mean of the individual scores. A higher
score indicates a better QoL. +e Schwab and England
Activities of Daily Living Scale (ADLS) was used for
assessing disability [17]. Functional dependency was defined
as an ADLS score less than 80% (80%� completely inde-
pendent; 70%� not completely independent) [18].
2.1. Data analysis. Data were processed using SPSS 20.0 for
Windows. NMS burden was defined as follows: mild (NMSS
1-20); moderate (NMSS 21-40); severe (NMSS 41-70); and
very severe (NMSS> 70) [10]. Each domain of the NMSS was
expressed as a percentage: (score/total score)× 100. +e
patients were classified according to H&Y-OFF (1, stage I; 2,
stage II; 3, stage III; 4, stage IV /V) and NMS burden (A: 0-
20; B: 21-40; C: 41-70; D: ≥ 71) in 16 stages (HY.NMSB): 1A,
1B, 1C, 1D, 2A, 2B, 2C, 2D, 3A, 3B, 3C, 3D, 4A, 4B, 4C, and
4D. PDQ-39 was expressed as a Summary Index (PDQ-
39SI): (score/156)× 100. For comparisons between patients
with a different H&Y stage, NMS burden stage, and/or
HY.NMSB stage, chi-squared, ANOVA, and/or Man-
n–Whitney–Wilcoxon test were applied. With the aim of
determining if the HY.NMSB contributes to the patient’s
QoL independently of other factors, a multiple regression
analysis was conducted (PDQ-39SI as dependent variable).
A p value< 0.05 was considered significant.
2.2. Standard Protocol Approvals, Registrations, and Patient
Consent. For this study, we received approval from the
Comité de Ética de la Investigación Cĺınica de Galicia from
Spain (2014/534; 02/DEC/2014). Written informed consents
from all participants in this study were obtained before the
start of the study. COPPADIS-2015 was classified by the
AEMPS (Agencia Española del Medicamento y Productos
Sanitarios) as a postauthorization prospective follow-up
study with the code COH-PAK-2014-01.
Parkinson’s Disease 3
3. Results
A total of 603 PD patients (62.7± 8.9 years old; 59.5%males)
from the COPPADIS cohort were included in the analysis.
+emean disease duration was 5.7± 4.5 years. One-hundred
and twenty-eight (22.9%) patients were in stage I of H&Y,
407 (67.5%) in stage II of H&Y, 49 (8.1%) in stage III of
H&Y, and only 9 (1.5%) in stage IV/V of H&Y. +e mean
NMSS total score was 46.7± 38.2, presenting 162 (26.9%)
patients with mild NMS burden, 174 (28.8%) with moderate
NMS burden, 140 (23.2%) with severe NMS burden, and 127
(21.1%) with very severe NMS burden. No patient presented
absence of nonmotor symptoms (NMSS� 0). Data about
PD-related variables are shown in Table SM 1. When H&Y
and NMS burden were combined (HY.NMSB), a higher
percentage of patients with severe or very severe NMS
burden in advanced H&Y stages (III and/or IV/V)
(p< 0.0001) was observed (Figure 1).
A worse QoL and a greater disability were associated
with a higher H&Y stage. Specifically, the PDQ-39SI and the
EUROHIS-QOL8 total score were significantly lower and
higher, respectively, in patients with a lower H&Y (Table 1
and Figure 2(a)). +e ADLS score was higher (indicative of
lower disability) in patients with a lower H&Y (Table 1).
When patients with a consecutive stage of H&Y were
compared, the most significant differences were observed
between patients with a stage II of H&Y and those ones with
stage III, but no differences were observed between patients
with a stage III of H&Y and those ones with stage IV (only 9
patients in this last subgroup) (Table 1). QoL and disability
were related to NMS burden as well, so the higher the NMS
burden stage, the worse the QoL, and the greater the dis-
ability (Table 2 and Figure 2(b)). After classifying partici-
pants by combining both scales, H&Y and NMSS (NMSB),
QoL and disability were related to the HY.NMSB stage
(Figure 2(c)): PDQ-39SI, from 6.7± 4.9 (HY.NMSB 1A) to
42.9± 11.9 (HY.NMSB 4D) (p< 0.0001); EUROHIS-QOL8
total score, from 4.1± 0.5 (HY.NMSB 1A) to 3.1± 0.6
(HY.NMSB 3D) (p< 0.0001; only 1 patient in the stage 4B
but with a score of 4.5); and ADLS score, from 94.9± 5.7
(HY.NMSB 1A) to 55± 19.1 (HY.NMSB 4D) (p< 0.0001).
With regard to our hypothesis, it was observed that patients
with a lower stage of H&Y could have a worse QoL and/or a
greater disability if they had a greater NMS burden (Tables 3
and 4). For example, patients with stage I of H&Y and very
severe NMS burden (HY.NMSB 1D; n� 15) compared to
patients with stage II of H&Y but mild NMS burden
(HY.NMSB 2A; n� 101) had a higher PDQ-39SI (28.6± 17.1
vs 7.9± 5.8; p< 0.0001) and a lower PQ-10 (6.4± 1.5 vs
7.9± 1.2; p< 0.0001), EUROHIS-QOL8 (3.5± 0.4 vs
4.1± 0.4p< 0.0001), and ADLS score (88± 6.8 vs 91.8± 5.9;
p � 0.025) (Table 3 and Figure 2). Even PDQ-39SI
(198± 11.9 vs 13.8± 9.8; p � 0.003) and EUROHIS-QOL8
score (3.6± 0.5 vs 3.9± 0.5; p � 0.030), we are significantly
higher and lower, respectively, in those patients with stage I
of H&Y and severe NMS burden HY.NMSB 1C; n� 27) than
those in ones with stage< II of H&Y and moderate NMS
burden (HY.NMS burden 2B; n� 125) (Table 3
and Figure 2). When patients with a stage II of H&Y
were compared with those ones with a stage III, a worse QoL
was observed in patients with stage II and very severe NMS
burden (HY.NMSB 2D; n� 91) than those in patients with a
stage III of H&Y but mild NMS burden (HY.NMSB 3A;
n� 6) or moderate NMS burden� (HY.NMSB 3B; n� 9):
PDQ-39SI 31.8± 3.8 vs 14.2± 10.9 p � 0.003; 31.8 ±13.8 vs.
21.5± 7.9 (p � 0.029): PQ-10, 6.2± 1.6 vs 8.5± 1.5
(p � 0.003); EUROHIS-QOL8, 3.8± 0.6 vs 3.6± 0.4
(p � 0.048) (Table 4 and Figure 2).
In a simple linear regression model, the HY.NMSB scale
predicted the PDQ-39SI: β� 0.480; CI 95%, 1.981 – 2.661;
p< 0.0001. After adjustment to other covariates (age, gen-
der, disease duration, levodopa equivalent daily dose,
UPDRS-IV, FOGQ, and BDI-II), the HY.NMSB stage
contributed significantly to the patient’s QoL (PDQ-39SI as
dependent variable) as well: adjusted R-squared 0.591; β �
0.089; CI 95%, 0.098 – 0.770; p � 0.011 (Table 2. SM). As
compared to the classical H&Y stage alone (not significant in
the model), the HY.NMS was multiplied by 12.7 the size
effect over the PDQ-39SI (β standardized coefficient of 0.007
for the H&Y in a model with age, gender, disease duration,
levodopa equivalent daily dose, UPDRS-IV, FOGQ, BDI-II,
and NMSS (p � 0.823) vs 0.089 for the HY.NMS in the
model with the same covariates included except the NMSS
(p � 0.011)).
4. Discussion
+e present study observed that the use in PD patients of a
scale that combines the H&Y stage with the NMSS
(HY.NMSB) could be useful since it would not only inform
about motor and nonmotor aspects but would also serve to
know how is the patient’s QoL and autonomy for ADL. +is
is relevant because many PD patients can be in stages I to III
of H&Y for many years and stratification regarding NMS
burden providing useful information not only for diagnosis
but also for monitoring the outcome and ideally the response
to a medication.
Ray Chaudhuri et al. [11] proposed a new strategy for
clinical classification of PD patients using the NMSS in 5
stratified levels of burden (0�no NMS; 1�NMSS, 1-20;
2�NMSS, 21-40; 3�NMSS, 41-70; 4�NMSS> 70) and
suggested that this simple assessment could be added to
existing motor-based staging (i.e., H & Y) to complement
PD assessment and avoid overlooking the weight of the
NMS. In 951 PD patients, these authors observed a signif-
icant influence of NMS burden on disability and QoL,
highlighting the need to include an NMS evaluation for a
complete assessment of PD patients. We observed the same
in 603 PD patients from the COPPADIS cohort. However,
here, we define specifically a scale (HY.NMSB) combining
the H&Y stage with the NMS burden: firstly, a number for
the H&Y from 1 (stage I) to 4 (stage IV/V); secondly, a letter
for the NMS burden from A (non NMS or mild NMS
burden; NMSS 0-20) to D (very severe burden; NMSS> 70).
Combining the number with the letter, a total of 16 stages are
defined, from HY.NMSB 1A (H&Y I and non-NMS/mild
NMS burden) to 4D (H&Y IV/V and very severe NMS
burden). PD patients without NMS (i.e., NMSS total
4 Parkinson’s Disease
score� 0) are rare (none in this cohort), but in any case, they
are included as “A” because there is really no difference
between, for example, a patient with NMSS total score� 0
and another one with NMSS total score� 1 or 3. So, “A” is
defined as a patient without NMS or mild NMS burden. On






























Figure 1: Total number (a) and percentage (b) of PD patients presenting with different stages of the HY.NMSB scale (from 1A to 4D)
(n� 603).
Table 1: Quality of life (PDQ-39SI and EUROHIS-QOL8) and disability (ADLS score) in PD patients with regard to Hoehn and Yahr stage
(s� 603).
H&Y 1, N� 138 H&Y 2, N� 407 H&Y 3, N� 49 H&Y 4, N� 9 pa pb pc pd
PDQ-39SI 13.3± 12.1 17.1± 12.9 30.9± 15.3 30.3± 15.3 <0.0001 0.037 <0.0001 0.908
Mobility 10.9± 14.2 16.1± 18 41.6± 23.8 37.2± 24.3 <0.0001 0.036 <0.0001 0.613
Activities of Daily Living 13.4± 14.3 18.3± 18.1 33.6± 24 29.1± 19.1 <0.0001 0.023 <0.0001 0.604
Emotional well-being 18.9± 16.9 21.6± 20.7 34.3± 21.9 32.8± 13.2 <0.0001 0.372 <0.0001 0.846
Stigma 12.3± 17 13.2± 19.7 16.1± 22.1 22.9± 32.7 0.316 0.839 0.341 0.432
Social support 6.8± 14.3 8.6± 16.9 9.7± 19.7 12.9± 22.1 0.497 0.492 0.686 0.656
Cognition 14.9± 16.4 20.1± 18.1 27.2± 18.9 31.2± 17.9 <0.0001 0.015 0.011 0.553
Communication 8.8± 13.8 9.5± 14.2 17.3± 19.7 19.4± 17.6 0.001 0.522 0.001 0.766
Pain and discomfort 21.1± 19.9 26.9± 22.9 42.5± 22.5 40.7± 28.9 <0.0001 0.065 <0.0001 0.835
PQ-10 7.5± 1.5 7.2± 6.2 6.2± 2.1 6.9± 1.4 <0.0001 0.234 <0.0001 0.375
EUROHIS-QOL8 3.9± 0.5 3.8± 0.5 3.3± 0.6 3.7± 0.5 <0.0001 0.117 <0.0001 0.135
Quality of life 3.9± 0.7 3.8± 0.7 3.2± 0.8 3.8± 0.4 <0.0001 0.207 <0.0001 0.063
Health status 3.4± 0.8 3.1± 0.9 2.5± 0.9 2.9± 0.8 <0.0001 0.012 <0.0001 0.296
Energy 3.9± 0.8 3.7± 0.8 3.2± 0.8 3.7± 1.1 <0.0001 0.195 <0.0001 0.156
Autonomy for ADL 3.8± 0.7 3.6± 0.8 2.8± 0.8 3.1± 0.8 <0.0001 0.023 <0.0001 0.289
Self-esteem 3.9± 0.7 3.8± 0.8 3.4± 0.9 3.4± 0.7 0.001 0.437 0.001 0.863
Social relationships 4± 0.7 4.1± 0.7 3.7± 0.8 4± 0.9 0.021 0.890 0.004 0.388
Economic capacity 3.9± 0.7 3.7± 0.8 3.7± 1 3.9± 0.7 0.414 0.819 0.160 0.546
Habitat 4.3± 0.7 4.2± 0.7 4.1± 0.8 4.4± 0.5 0.287 0.832 0.112 0.161
ADLS score 93.5± 6.9 87.8± 9.4 77.1± 13.1 72.5± 23.8 <0.0001 <0.0001 <0.0001 0.416
Functional dependency (%) 0.7 8.8 42.9 37.5 <0.0001 <0.0001 <0.0001 0.546
Chi-squared, Mann–Whitney–Wilcoxon, and ANOVA test were applied.+e results represent percentages or mean±SD; pa, all groups; pb, H&Y 2 vs H&Y 1;
pc, H&Y 3 vs H&Y 2; pd, H&Y 4 vs H&Y 3. ADL, Activities of Daily Living; ADLS, Schwab and England Activities of Daily Living Scale; EUROHIS-QOL8,
EUROHIS-QOL 8-item index; H&Y, Hoehn and Yahr; PDQ-39SI, 39-item Parkinson’s Disease Quality of Life Questionnaire Summary Index.
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very advanced PD patients with regard to motor stage (H&Y
IV and V) are considered together as number 4. After ap-
plying this scale (HY.NMSB) for the first time, we observed
that QoL and disability were related to H&Y but NMS
burden as well, so patients with a lower H&Y but a greater
NMS burden can perceive a worse QoL and greater disability
than patients with a higher H&Y stage but lower NMS
burden. Conventionally, H&Y stages I and II represent mild
Table 2: Quality of life (PDQ-39SI and EUROHIS-QOL8) and disability (ADLS score) in PD patients with regard to nonmotor symptoms









a pb pc pd
PDQ-39SI 7.7± 5.7 13.8± 9.7 19.9± 10.7 32.9± 14.4 <0.0001 <0.0001 <0.0001 <0.0001
Mobility 6.2± 11.5 12.7± 15.6 19.7± 15.9 35.3± 22.9 <0.0001 <0.0001 0.029 <0.0001
Activities of Daily Living 9.5± 11.1 15.8± 15.4 19.8± 16.7 32.4± 23.3 <0.0001 <0.0001 <0.0001 <0.0001
Emotional well-being 9.9± 10.8 15.6± 13.9 26.6± 18.7 41.6± 22.6 <0.0001 0.001 0.149 <0.0001
Stigma 7.6± 14.1 13.7± 18.9 10.8 ±16.2 22.9± 25.5 <0.0001 0.025 0.001 <0.0001
Social support 2.2± 8.9 4.9± 12.8 10.6± 17.5 18.6± 21.9 <0.0001 <0.0001 <0.0001 0.001
Cognition 7.2± 9.6 16.2± 13.9 24.6± 16.2 34.9± 20.1 <0.0001 <0.0001 0.036 <0.0001
Communication 3.5± 7.3 8.3± 12.4 11.6± 14.7 19.3± 19.7 <0.0001 <0.0001 <0.0001 <0.0001
Pain and discomfort 14.7± 15.6 20.7± 18.9 30.7± 19.6 47.4± 24.8 <0.0001 0.002 <0.0001 <0.0001
PQ-10 7.9± 1.2 7.5± 1.4 6.9± 1.4 6.1± 1.7 <0.0001 <0.0001 0.003 <0.0001
EUROHIS-QOL8 4.1± 0.5 3.9± 0.4 3.6± 0.5 3.3± 0.6 <0.0001 <0.0001 <0.0001 <0.0001
Quality of life 4.1± 0.5 3.9± 0.6 3.7± 0.7 3.3± 0.8 <0.0001 0.005 0.001 <0.0001
Health status 3.5± 0.8 3.3± 0.8 3± 0.8 2.6± 0.9 <0.0001 0.001 0.006 <0.0001
Energy 4.2± 0.7 3.8± 0.7 3.6± 0.8 3.2± 0.9 <0.0001 <0.0001 0.004 <0.0001
Autonomy for ADL 4± 0.7 3.8± 0.8 3.4± 0.8 3± 0.9 <0.0001 0.001 <0.0001 <0.0001
Self-esteem 4.2± 0.6 3.9± 0.7 3.6± 0.7 3.3± 0.9 <0.0001 0.010 <0.0001 0.001
Social relationships 4.4± 0.6 4.1± 0.6 3.9± 0.7 3.6± 0.8 <0.0001 <0.0001 0.059 <0.0001
Economic capacity 4.1± 0.8 3.9± 0.7 3.8± 0.7 3.5± 0.9 <0.0001 0.079 0.180 0.001
Habitat 4.4± 0.7 4.3± 0.6 4.2± 0.7 3.9± 0.7 <0.0001 0.105 0.123 0.011
ADLS score 92.9± 6.1 90.2± 8.3 86.5± 10.4 80.5± 12.9 <0.0001 0.001 <0.0001 <0.0001
Functional
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Figure 2: PDQ-39SI and EUROHIS-QOL8 scores in patients with regard to the H&Y (a), the nonmotor symptoms burden (NMSB) (b), and
both (HY.NMSB) (c) (n� 603).
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PD, but this qualification cannot be supported attending the
load of NMS and any domain/s they belong. +e NMS
present in PD may be very variable in number and type, and
they maintain only a moderate association with the motor
disturbances [10, 11, 19, 20]. In fact, although as expected,
patients with mild NMS burden (A; 39.8%) were the most
frequent in the group with a stage I of H&Y and patients with
very severe NMS burden (D; 44.4%) in the group with H&Y
IV/V; more than 30% of the patients in stage I of H&Y had
severe or very severe NMS burden. Clinical and
Table 4: Quality of life (PDQ-39SI and EUROHIS-QOL8) and disability (ADLS score) in patients with stages 2C, 2D, 3A, or 3B of the HY-
NMSB scale.
2C, N� 93 2D, N� 91 3A, N� 6 3B, N� 9 pa pb pc pd
PDQ-39SI 18.5± 10.2 31.8± 13.8 14.2± 10.9 21.5± 7.9 0.003 0.029 0.173 0.238
Mobility 17.2± 14.9 32± 2.1 27.1± 31.2 27.5± 16.3 0.372 0.722 0.713 0.048
Activities of Daily Living 18.4± 16.4 31.1± 23.3 6.9± 7.7 25.9± 11.7 0.005 0.722 0.081 0.084
Emotional well-being 25.6± 20.1 41.7± 23.1 15.9± 20.8 24.5± 19.5 0.014 0.036 0.203 0.953
Stigma 9.3± 15.1 22.4± 24.4 7.3± 15 6.9± 14.1 0.109 0.073 0.636 0.749
Social support 9.9± 16.7 19.1± 21.9 0± 0 2.8± 4.2 0.015 0.048 0.081 0.526
Cognition 24.4± 15.9 35.7± 21.2 1± 2.6 24.3± 13.4 <0.0001 0.109 <0.0001 0.948
Communication 9.5± 13.6 18.4± 18.7 2.8± 6.8 13.9± 13.8 0.025 0.633 0.183 0.226
Pain and discomfort 30.9± 19.6 46.1± 24.6 34.7± 22.6 28.7± 19.6 0.209 0.031 0.830 0.673
PQ-10 7± 1.4 6.2± 1.6 8.5± 1.5 7.2± 1.3 0.003 0.069 0.025 0.620
EUROHIS-QOL8 3.7± 0.4 3.3± 0.6 3.8± 0.6 3.6± 0.4 0.048 0.169 0.590 0.377
Quality of life 3.7± 0.7 3.4± 0.7 4± 0.9 3.6± 0.5 0.108 0.563 0.462 0.328
Health status 3± 0.7 2.6± 0.9 3.2± 0.7 2.7± 0.5 0.134 0.774 0.598 0.139
Energy 3.7± 0.7 3.2± 0.9 3.8± 0.4 3.6± 0.5 0.078 0.293 0.553 0.544
Autonomy for ADL 3.4± 0.7 3± 0.9 3± 0.6 3.2± 0.7 0.819 0.625 0.124 0.340
Self-esteem 3.6± 0.7 3.2± 0.9 4± 0.9 3.8± 0.7 0.083 0.112 0.335 0.696
Social relationships 4± 0.7 3.6± 0.8 4± 0.7 3.9± 0.6 0.115 0.322 0.649 0.520
Economic capacity 3.9± 0.7 3.5± 0.9 4.2± 0.7 3.8± 1.1 0.064 0.231 0.311 0.855
Habitat 4.3± 0.6 3.9± 0.7 4.2± 0.7 4.1± 0.9 0.369 0.255 0.713 0.751
ADLS score 86.5± 9.3 81.8± 11.5 90± 8.9 83.3± 10 0.091 0.769 0.421 0.278
FD (%) 9.7 25.3 0 22.2 0.187 0.601 0.556 0.250
Chi-squared andMann–Whitney–Wilcoxon test were applied.+e results represent percentages or mean ± SD; pa, 2D vs 3A; pb, 2D vs 3B; pc, 2C vs 3A; pd, 2C
vs 3B. ADLS, Schwab and England Activities of Daily Living Scale; EUROHIS-QOL8, EUROHIS-QOL 8-item index; PDQ-39SI, 39-item Parkinson’s Disease
Quality of Life Questionnaire Summary Index.
Table 3: Quality of life (PDQ-39SI and EUROHIS-QOL8) and disability (ADLS score) in patients with stages 1C, 1D, 2A, or 2B of the
HY-NMSB scale.
1C, N� 27 1D, N� 15 2A, N� 101 2B, N� 125 pa pb pc pd
PDQ-39SI 19.8± 11.9 28.6± 17.1 7.9± 5.8 13.8± 9.8 <0.0001 <0.0001 <0.0001 0.003
Mobility 18.1± 14.9 27.8± 17.7 6.1± 10.5 13± 16.2 <0.0001 0.001 <0.0001 0.035
Activities of Daily Living 16.5± 15.2 28.3± 18.3 10.9± 12.4 15.9± 16.1 <0.0001 0.007 0.056 0.710
Emotional well-being 28.7± 16.4 35.5± 21.3 8.9± 9.4 14.9± 13.7 <0.0001 <0.0001 <0.0001 <0.0001
Stigma 16.4± 20.4 23.8± 23.9 8.4± 15.7 13.9± 19.9 0.013 0.140 0.030 0.448
Social support 13.6± 17.8 19.4± 22.6 2.4± 9.9 5.3± 13.8 <0.0001 0.003 <0.0001 0.005
Cognition 21.9± 17.4 32.5± 18.8 8.3± 9.6 15.9± 13.7 <0.0001 0.001 <0.0001 0.099
Communication 14.2± 15.9 20.6± 19.6 4.1± 8.4 7.9± 12.1 <0.0001 0.007 <0.0001 0.026
Pain and discomfort 27.8± 20.1 38.3± 27.4 13.5± 13.5 21.2± 20.3 <0.0001 0.010 <0.0001 0.053
PQ-10 6.9± 1.6 6.4± 1.5 7.9± 1.2 7.5± 1.5 <0.0001 0.008 0.008 0.201
EUROHIS-QOL8 3.6± 0.5 3.5± 0.4 4.1± 0.4 3.9± 0.5 <0.0001 0.004 <0.0001 0.030
Quality of life 3.6± 0.6 3.2± 0.6 4.1± 0.6 3.9± 0.6 <0.0001 <0.0001 0.001 0.048
Health status 3.2± 0.9 3.2± 0.6 3.6± 0.7 3.3± 0.8 0.014 0.726 0.051 0.888
Energy 3.4± 0.7 3.4± 0.6 4.1± 0.6 3.8± 0.7 <0.0001 0.025 <0.0001 0.009
Autonomy for ADL 3.5± 0.7 3.5± 0.5 4.1± 0.6 3.7± 0.7 <0.0001 0.065 <0.0001 0.089
Self-esteem 3.6± 0.8 3.5± 0.6 4.2± 0.6 3.9± 0.7 <0.0001 0.015 <0.0001 0.016
Social relationships 3.9± 0.6 3.8± 0.6 4.4± 0.6 4.2± 0.6 0.001 0.023 <0.0001 0.022
Economic capacity 3.7± 0.7 3.4± 0.7 3.9± 0.8 3.9± 0.6 0.010 0.025 0.014 0.054
Habitat 3.9± 0.8 3.9± 0.7 4.4± 0.6 4.3± 0.6 0.005 0.001 0.160 0.114
ADLS score 92.6± 7.1 88± 6.8 91.8± 5.9 89.5± 8 0.025 0.246 0.461 0.061
FD (%) 0 0 1 4 0.871 0.562 0.789 0.371
Chi-squared andMann–Whitney–Wilcoxon test were applied.+e results represent percentages or mean± SD; pa, 1D vs 2A; pb, 1D vs 2B; pc, 1C vs 2A; pd, 1C
vs 2B. ADLS, Schwab and England Activities of Daily Living Scale; EUROHIS-QOL8, EUROHIS-QOL 8-item index; PDQ-39SI, 39-item Parkinson’s Disease
Quality of Life Questionnaire Summary Index.
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Table 5: COPPADIS study group.
Name (last name, first
name) Location Role Contribution
Astrid Adarmes,
Daniela
Hospital Universitario Virgen del Roćıo, Sevilla,
Spain Site investigator
Evaluation of participants and/
or data management





Hospital Álvaro Cunqueiro, Complejo
Hospitalario Universitario de Vigo (CHUVI),
Vigo, Spain
Site investigator /PI
Coordination at the center




Hospital Universitario Ramón y Cajal, Madrid,
Spain Site investigator




Hospital Universitario Cĺınico San Carlos,
Madrid, Spain Site investigator
Evaluation of participants and/
or data management
Aneiros Dı́az, Ángel Complejo Hospitalario Universitario de Ferrol(CHUF), Ferrol, A Coruña, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Álvarez, Ignacio Hospital Universitari Mutua de Terrassa, Terrassa,Barcelona, Spain Site investigator
Evaluation of participants and/
or data management
Álvarez Sauco, Maŕıa Hospital General Universitario de Elche, Elche,Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Arnáiz, Sandra Complejo Asistencial Universitario de Burgos,Burgos, Spain Site investigator
Evaluation of participants and/
or data management





Complejo Hospitalario de Navarra, Pamplona,
Spain Site investigator
Evaluation of participants and/
or data management
Aguilar, Miquel Hospital Universitari Mutua de Terrassa, Terrassa,Barcelona, Spain Site investigator




Consorci Sanitari Integral, Hospital General de L
´Hospitalet, L´Hospitalet de Llobregat, Barcelona,
Spain
Site investigator /PI
Coordination at the center




Hospital de Tortosa Verge de la Cinta (HTVC),
Tortosa, Tarragona, Spain Site investigator
Evaluation of participants and/
or data management
Bejr-Kasem, Helena Hospital de Sant Pau, Barcelona, Spain Site investigator Evaluation of participants and/or data management
Blázquez Estrada,
Marta
Hospital Universitario Central de Asturias,
Oviedo, Spain Site investigator Evaluation of participants
Bot́ı González, Maria
Ángeles
Hospital Universitari Mutua de Terrassa, Terrassa,
Barcelona, Spain Site investigator
Neuropsychologist; evaluation
of participants
Borrué, Carmen Hospital Infanta Sof́ıa, Madrid, Spain Site investigator /PI
Coordination at the center




Hospital Universitari Mutua de Terrassa, Terrassa,
Barcelona, Spain Site investigator Nurse study coordinator
Cabello González,
Carolina
Complejo Hospitalario de Navarra, Pamplona,
Spain Site investigator Scheduling of evaluations
Cabo López, Iria Complejo Hospitalario Universitario dePontevedra (CHOP), Pontevedra, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Caballol, Nuria Consorci Sanitari Integral, Hospital MoisésBroggi, Sant Joan Despı́, Barcelona, Spain. Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Cámara Lorenzo, Ana Hospital Cĺınic de Barcelona, Barcelona, Spain Site investigator Nurse study coordinator
Carrillo, Fátima Hospital Universitario Virgen del Roćıo, Sevilla,Spain Site investigator




Hospital Universitario de Canarias, San Cristóbal
de la Laguna, Santa Cruz de Tenerife, Spain Site investigator /PI Coordination at the center
Casas, Elena Complejo Asistencial Universitario de Burgos,Burgos, Spain Site investigator




Name (last name, first
name) Location Role Contribution
Catalán, Maria Joé Hospital Universitario Cĺınico San Carlos,Madrid, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Clavero, Pedro Complejo Hospitalario de Navarra, Pamplona,Spain Site investigator
Evaluation of participants and/
or data management
Cortina Fernández, A Complejo Hospitalario Universitario de Ferrol(CHUF), Ferrol, A Coruña, Spain Site investigator
Coordination of blood
extractions
Cosgaya, Marina Hospital Cĺınic de Barcelona, Barcelona, Spain Site investigator Evaluation of participants and/or data management
Cots Foraster, Anna Institut d’Assistència Sanitària (IAS) - Instituı́Cátala de la Salud. Girona, Spain Site investigator
Evaluation of participants and/
or data management
Crespo Cuevas, Ane Hospital del Mar, Barcelona, Spain. Site investigator Evaluation of participants and/or data management
Cubo, Esther Complejo Asistencial Universitario de Burgos,Burgos, Spain Site investigator /PI
Coordination at the center




Complejo Hospitalario Universitario de Ferrol
(CHUF), Ferrol, A Coruña, Spain Site investigator
Nurse study coordinator
Evaluation of participants and/
or data management
De Fábregues, Oriol Hospital Universitario Vall d´Hebron, Barcelona,Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Dı́ez Fairen, M Hospital Universitari Mutua de Terrassa, Terrassa,Barcelona, Spain Site investigator
Evaluation of participants and/
or data management
Erro, Elena Complejo Hospitalario de Navarra, Pamplona,Spain Site investigator
Evaluation of participants and/
or data management
Escalante, Sonia Hospital de Tortosa Verge de la Cinta (HTVC),Tortosa, Tarragona, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
stelrich Peyret, Elena Institut d’Assistència Sanitària (IAS) - Instituı́Cátala de la Salud. Girona, Spain Site investigator




Complejo Hospitalario Universitario de Ferrol
(CHUF), Ferrol, A Coruña, Spain Site investigator Neuroimaging studies
Gámez, Pedro Complejo Asistencial Universitario de Burgos,Burgos, Spain Site investigator
Evaluation of participants and/
or data management
Gallego, Mercedes Hospital La Princesa, Madrid, Spain Site investigator Evaluation of participants and/or data management
Garćıa Caldentey, Juan Centro Neurológico Oms 42, Palma de Mallorca,Spain Site investigator /PI
Coordination at the center




Hospital Universitario Virgen Macarena, Sevilla,
Spain Site investigator




Hospital Universitario Virgen Macarena, Sevilla,
Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Gastón, Itziar Complejo Hospitalario de Navarra, Pamplona,Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management





Hospital Universitario Virgen del Roćıo, Sevilla,
Spain Site investigator Genetic studies coordination
Gómez Mayordomo,
Vı́ctor Hospital Cĺınico San Carlos, Madrid, Spain Site investigator
Evaluation of participants and/
or data management
González Aloy, Javier Institut d’Assistència Sanitària (IAS) - Instituı́Cátala de la Salud. Girona, Spain Site investigator




Hospital Universitario Marqués de Valdecilla,
Santander, Spain Site investigator




Name (last name, first
name) Location Role Contribution
González Ardura,
Jessica
Hospital Universitario Lucus Augusti (HULA),
Lugo, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
González Garcı́a,
Beatriz Hospital La Princesa, Madrid, Spain Site investigator Nurse study coordinator
González Palmás,
Maria Josefa
Complejo Hospitalario Universitario de
Pontevedra (CHOP), Pontevedra, Spain Site investigator




Hospital Universitario de Canarias, San Cristóbal
de la Laguna, Santa Cruz de Tenerife, Spain Site investigator
Evaluation of participants and/
or data management
Golpe Dı́az, Ana Complejo Hospitalario Universitario de Ferrol(CHUF), Ferrol, A Coruña, Spain Site investigator
Laboratory analysis
coordination
Grau Solá, Mireia Consorci Sanitari Integral, Hospital MoisésBroggi, Sant Joan Despı́, Barcelona, Spain Site investigator
Evaluation of participants and/
or data management
Guardia, Gemma Hospital Universitari Mutua de Terrassa, Terrassa,Barcelona, Spain Site investigator
Evaluation of participants and/
or data management
Hernández Vara, Jorge Hospital Universitario Vall d´Hebron, Barcelona,Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Horta Barba, Andrea Hospital de Sant Pau, Barcelona, Spain Site investigator Neuropsychologist; evaluationof participants
Idoate Calderón,
Daniel
Complejo Hospitalario Universitario de
Pontevedra (CHOP), Pontevedra, Spain Site investigaor
Neuropsychologist; evaluation
of participants
Infante, Jon Hospital Universitario Marqués de Valdecilla,Santander, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Jesús, Silvia Hospital Universitario Virgen del Roćıo, Sevilla,Spain Site investigator
Evaluation of participants and/
or data management
Kulievsky, Jaime Hospital de Sant Pau, Barcelona, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Kurtis, Mónica Hospital Ruber Internacional, Madrid, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Labandeira, Carmen
Hospital Álvaro Cunqueiro, Complejo
Hospitalario Universitario de Vigo (CHUVI),
Vigo, Spain
Site investigator Evaluation of participants and/or data management
Labrador Espinosa,
Miguel Ángel
Hospital Universitario Virgen del Roćıo, Sevilla,
Spain Site investigator Neuroimaging data analysis
Lacruz, Francisco Complejo Hospitalario de Navarra, Pamplona,Spain Site investigator
Evaluation of participants and/
or data management
Lage Castro, Melva Complejo Hospitalario Universitario dePontevedra (CHOP), Pontevedra, Spain Site investigator
Evaluation of participants and/
or data management
Legarda, Inés Hospital Universitario Son Espases, Palma deMallorca, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
López Ariztegui, Nuria Complejo Hospitalario de Toledo, Toledo, Spain Site investigator /PI Evaluation of participants and/or data management
López Dı́az, Luis
Manuel Hospital Da Costa de Burela, Lugo, Spain Site investigator
Evaluation of participants and/
or data management
López Manzanares,
Lydia Hospital La Princesa, Madrid, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
López Seoane, Balbino Complejo Hospitalario Universitario de Ferrol(CHUF), Ferrol, A Coruña, Spain Site investigator Neuroimaging studies
Lucas del Pozo, Sara Hospital Universitario Vall d´Hebron, Barcelona,Spain Site investigator
Evaluation of participants and/
or data management
Maćıas, Yolanda Fundación Hospital de Alcorcón, Madrid, Spain Site investigator Evaluation of participants and/or data management
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Table 5: Continued.
Name (last name, first
name) Location Role Contribution
Mata, Marina Hospital Infanta Sof́ıa, Madrid, Spain Site investigator Evaluation of participants and/or data management
Mart́ı Andres, Gloria Hospital Universitario Vall d´Hebron, Barcelona,Spain Site investigator
Evaluation of participants and/
or data management
Mart́ı, Maria José Hospital Cĺınic de Barcelona, Barcelona, Spain Site investigator /PI
Coordination at the center




Hospital Universitario Ramón y Cajal, Madrid,
Spain Site investigator /PI
Coordination at the center




Centro Nacional de Epidemiologı́a y CIBERNED,
Instituto de Salud Carlos III. Madrid
Collaborator in statistical
and methods analysis Methods and statistical reviewer
McAfee, Darrian University of Pennsylvania, Philadelphia Collaborator in englishstyle English style reviewer
Meit́ın, Maria Teresa Hospital Da Costa de Burela, Lugo, Spain Site investigator Evaluation of participants and/or data management
Menéndez González,
Manuel
Hospital Universitario Central de Asturias,
Oviedo, Spain Site investigator /PI
Coordination at the center




Hospital Universitario Virgen del Roćıo, Sevilla,
Spain Site investigator
Evaluation of participants and/
or data management
Mir, Pablo Hospital Universitario Virgen del Roćıo, Sevilla,Spain Site investigator /PI
Coordination at the center




Complejo Asistencial Universitario de Burgos,
Burgos, Spain Site investigator
Evaluation of participants and/
or data management
Morales Casado, Maria
Isabel Complejo Hospitalario de Toledo, Toledo, Spain. Site investigator




Complejo Hospitalario Universitario de Ferrol
(CHUF), Ferrol, A Coruña, Spain Site investigator Neuroimaging studies
Nogueira, Vı́ctor Hospital Da Costa de Burela, Lugo, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Novo Amado, Alba Complejo Hospitalario Universitario de Ferrol(CHUF), Ferrol, A Coruña, Spain Site investigator Neuroimaging studies
Novo Ponte, Sabela Hospital Universitario Puerta de Hierro, Madrid,Spain. Site investigator
Evaluation of participants and/
or data management
Ordás, Carlos Hospital Rey Juan Carlos, Madrid, Spain, Madrid,Spain. Site investigator
Evaluation of participants and/
or data management
Pagonabarraga, Javier Hospital de Sant Pau, Barcelona, Spain Site investigator Evaluation of participants and/or data management
Isabel Pareés Hospital Ruber Internacional, Madrid, Spain Site investigator Evaluation of participants and/or data management
Pascual-Sedano, Berta Hospital de Sant Pau, Barcelona, Spain Site investigator Evaluation of participants and/or data management
Pastor, Pau Hospital Universitari Mutade Terrassa, Terrassa,Barcelona, Spain Site investigator
Evaluation of participants and/
or data management
Pérez Fuertes, Aı́da Complejo Hospitalario Universitario de Ferrol(CHUF), Ferrol, A Coruña, Spain Site investigator Blood analysis
Pérez Noguera, Rafael Hospital Universitario Virgen Macarena, Sevilla,Spain Site investigator
Evaluation of participants and/
or data management
Planas-Ballvé, Ana Consorci Sanitari Integral, Hospital MoisésBroggi, Sant Joan Despı́, Barcelona, Spain Site investigator
Evaluation of participants and/
or data management
Planellas, Lluı́s Hospital Cĺınic de Barcelona, Barcelona, Spain Site investigator Evaluation of participants and/or data management
Prats, Marian Ángeles Institut d’Assistència Sanitària (IAS) - Instituı́Cátala de la Salud. Girona, Spain Site investigator




Name (last name, first
name) Location Role Contribution
Prieto Jurczynska,
Cristina
Hospital Rey Juan Carlos, Madrid, Spain, Madrid,
Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Puente, Vı́ctor Hospital del Mar, Barcelona, Spain Site investigator /PI
Coordination at the center




Hospital Universitario de Canarias, San Cristóbal
de la Laguna, Santa Cruz de Tenerife, Spain Site investigator
Evaluation of participants and/
or data management
Redondo, Nuria Hospital La Princesa, Madrid, Spain Site Investigator Evaluation of participants and/or data management
Rodŕıguez Méndez,
Luisa
Complejo Hospitalario Universitario de Ferrol
(CHUF), Ferrol, A Coruña, Spain Site investigator Blood analysis
Rodŕıguez Pérez,
Amparo Belén
Hospital General Universitario de Elche, Elche,
Spain Site investigator
Evaluation of participants and/
or data management
Roldán, Florinda Hospital Universitario Virgen del Roćıo, Sevilla,Spain Site investigator Neuroimaging studies
Ruı́z de Arcos, Maŕıa Hospital Universitario Virgen Macarena, Sevilla,Spain. Site investigator
Evaluation of participants and/
or data management
Ruı́z Mart́ınez, Javier Hospital Universitario Donostia, San Sebastián,Spain Site investigator
Evaluation of participants and/
or data management
Sánchez Alonso, Pilar Hospital Universitario Puerta de Hierro, Madrid,Spain Site investigator




Complejo Hospitalario Universitario de Ferrol
(CHUF), Ferrol, A Coruña, Spain Site investigator Neuroimaging studies
Sánchez Dı́ez, Gema Hospital Universitario Ramón y Cajal, Madrid,Spain Site investigator




Hospital Universitario Marqués de Valdecilla,
Santander, Spain Site investigator
Evaluation of participants and/
or data management
Santacruz, Pilar Hospital Cĺınic de Barcelona, Barcelona, Spain Site investigator Evaluation of participants and/or data management




José Clemente Complejo Hospitalario de Toledo, Toledo, Spain Site investigator
Evaluation of participants and/
or data management
Seijo, Manuel Complejo Hospitalario Universitario dePontevedra (CHOP), Pontevedra, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Sierra, Maŕıa Hospital Universitario Marqués de Valdecilla,Santander, Spain Site investigator
Evaluation of participants and/
or data management
Solano, Berta Institut d’Assistència Sanitària (IAS) - Instituı́Cátala de la Salud. Girona, Spain Site investigator /PI
Coordination at the center
Evaluation of participants and/
or data management
Suárez Castro, Ester Complejo Hospitalario Universitario de Ferrol(CHUF), Ferrol, A Coruña, Spain Site investigator
Evaluation of participants and/
or data management
Tartari, Juan Pablo Hospital Universitari Mutua de Terrassa, Terrassa,Barcelona, Spain Site investigator
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neuropathological data are now emerging supporting the
concept of the nonmotor dominant endophenotype [21],
and it seems necessary in daily practice to know the fre-
quency and the severity of NMS in PD patients, even in early
PD patients, because NMS burden could be significant, and
this one impacts on their QoL and contributes to disability
[7, 9, 15, 22]. Very recently, two PD subtypes have been
suggested [23, 24], and it would be of great interest to know
if very early PD patients with very severe NMS burden could
correspond with the body-first (bottom-up) type and those
with mild NMS burden with the brain-first (top-down) type.
+e application of the HY.NMSB scale could have dif-
ferent uses: (1) a fast and relatively simple way of knowing the
motor and nonmotor states of a PD patient, stratifying him/
her into a group (diagnosis value; first visit); (2) to monitor
the long-term evolution of the patient (prognosis value;
follow-up visits); (3) to monitor the response of a patient to a
specific therapeutic intervention. In fact, the NMSS total score
has been considered as the primary efficacy variable in recent
trials [25], and it is known that some NMS can be improved,
with dopaminergic medication or nondopaminergic medi-
cation [26]. In this context, the HY.NMSB could be used for
defining a specific population or as an outcome parameter in
clinical trials. For example, nabilone has very recently
demonstrated to improve NMS in PD patients in a phase 2
trial [27], being an interesting possibility to identify what
patients changed from a superior stage of the HY.NMSB to an
inferior stage (e.g., from 2C to 2 B). Finally, the HY-NMSB
scale could be useful to indirectly estimate the patient’s
perception of QoL and disability. +e correlation of H&Y,
NMSS, and NMS burden with QoL and disability has been
frequently reported [7–9, 22], including in PD patients from
the COPPADIS cohort [15, 18], but this is the first time that
the relationship considering both motor stage (H&Y) and
NMS burden (NMSS) at the same time has been analyzed, and
it is important because the influence of NMS burden on QoL
perception is critical. An inherent limitation of the proposed
classification (HY.NMSB) is the fact that the classification
according to NMS is carried out taking into account the total
NMS burden but without considering what exactly these
symptoms are. Importantly, some NMS could help clinical
practitioners to identify patients who are at different stages of
the disease, such as hallucinations, fainting, inability to
control body sphincters, or believing in unlikely facts [28].
Moreover, and compared with the International Parkinson
and Movement Disorder Society─Nonmotor Rating Scale
(MDS-NMS) [29], the NMSS collects the patient’s perception
about different NMS in the previous 4 weeks but does not
about nonmotor fluctuations.
A very important limitation is that our sample is not fully
representative of the PD population due to inclusion and
exclusion criteria (i.e., age limit, no dementia, no severe
comorbidities, and no second line therapies) which subse-
quently entails a bias toward early PD. +e majority of the
patients from this cohort were in the stage I or II of the H&Y
(90.4%), so the same analysis with the proposed classification
should be carried out in a cohort with more patients in ad-
vanced stages of H&Y. In spite of this and importantly, during
the first 5 to 10 years of the disease, many patients with PD will
be in stage II of theH&Y, and introducing theNMS burdenwill
help to differentiate the degree of nonmotor affectation, that
importantly correlates with QoL perception. In other words,
the results of the present study are applicable for a long time to
the majority of PD patients, especially in early young PD
patients. Second, all scales or questionnaires used for assessing
motor and NMS are validated except PQ-10 [8, 15]. +ird,
NMS were recorded with the NMSS, but specifically, as we
commented nonmotor fluctuations were not identified [30].
Fourth, the OFF state (12 hours without taking medication)
was considered for defining the H&Y stage because it repre-
sents a more natural state of the disease less conditioned by the
symptomatic effect of the medication. Moreover, in PD pa-
tients with motor fluctuations, the symptoms during the OFF
state mostly impact on QoL and autonomy. In any case,
previously, similar results applying the HY.NMSB were ob-
served when the H&Y stage was defined during the ON state in
149 PD patients from the CASINO cohort [8, 31]. In the
COPPADIS cohort, the results were similar as well when the
H&Y was defined during the ON state in those PD patients
with motor fluctuations (data not shown). Fifth, the time it
took to administer the HY.BMSB scale was not calculated.
Finally, this is a cross-sectional study, but the aim of the
COPPADIS-2015 study [12] is to follow-up the cohort for 5
years, so changes in HY.NMSB and the relationship with
changes in other variables could be analyzed.
In conclusion, this is the first time that a specific scale
combing the H&Y stage and the NMSS (HY.NMSB scale)
is applied in PD patients for knowing the relationship
with the patient’s QoL perception and disability regarding
the stage. +e HY.NMSB scale is simple and reflects the
degree of patient involvement more accurately than the
H&Y. Patients with a lower H&Y stage may be more
affected if they have a greater NMS burden. +ese results
need to be replicated in a larger and well-distributed
cohort of patients by motor stage.
Appendix
A. COPPADIS Study Group
+e authors in the COPPADIS Study Group have been listed
in Table 5.
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[8] D. Santos-Garćıa and R. de la Fuente-Fernández, “Impact of
non-motor symptoms on health-related and perceived quality
of life in Parkinson’s disease,” Journal of the Neurological
Sciences, vol. 332, no. 1-2, pp. 136–140, 2013.
[9] P. Martinez-Martin, C. Rodriguez-Blazquez, M. M. Kurtis,
and K. R. Chaudhuri, “+e impact of non-motor symptoms
on health-related quality of life of patients with Parkinson’s
disease,” Movement Disorders, vol. 26, no. 3, pp. 399–406,
2011.
[10] P. Martinez-Martin and K. Ray Chaudhuri, “prehensive
grading of Parkinson’s disease using motor and non-motor
assessments: addressing a key unmet need,” Expert Review of
Neurotherapeutics, vol. 18, no. 1, pp. 41–50, 2018.
[11] K. Ray Chaudhuri, J. M. Rojo, A. H. Schapira et al., “A
proposal for a comprehensive grading of Parkinson’s disease
severity combining motor and non-motor assessments:
meeting an unmet need,” PLoS One, vol. 8, Article ID e57221,
2013.
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“Non-motor symptoms burden, mood, and gait problems are
the most significant factors contributing to a poor quality of
life in non-demented Parkin.son’s dis.ease patien.ts: Results
from the COPPADIS Study Cohort,” Parkinsonism & Related
Disorders, vol. 66, pp. 151–157, 2019.
[16] N. S. d. Rocha, M. J. Power, D. M. Bushnell, and M. P. Fleck,
“+e EUROHIS-QOL 8-item index: comparative psycho-
metric properties to its parent WHOQOL-BREF,” Value in
Health, vol. 15, no. 3, pp. 449–457, 2012.
[17] R. S. Schwab and A. C. England, Parkinson’s disease,
pp. 152–7, E. And S. Livingstone, Edinburgh, Scotland, 1969.
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